A robust kit, standards, and software for identifying RNA binding protein targets

用于识别 RNA 结合蛋白靶标的强大试剂盒、标准品和软件

基本信息

  • 批准号:
    9410415
  • 负责人:
  • 金额:
    $ 127.8万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2017
  • 资助国家:
    美国
  • 起止时间:
    2017-09-20 至 2019-08-31
  • 项目状态:
    已结题

项目摘要

PROJECT SUMMARY After transcription, RNA molecules undergo a number of processing steps that regulate the spliced sequence, RNA expression level, subcellular localization, and initiation and rate of translation, and are each controlled by the activity of RNA binding proteins (RBPs). RNA processing plays critical roles in normal development, and altered RNA processing has been shown to cause familial Spinal Muscular Atrophy, Amyotrophic Lateral Sclerosis, and multiple cancer types. Identifying the RNA targets of the RBP mutated in these diseases is a critical first step towards a mechanistic understanding of the disease and, ultimately, development of targeted therapeutics. However, standardized methods for identification of RBP targets transcriptome-wide were lacking, as they required large sample input amounts, had high experimental failure rates, and required high amplification leading to significant wasted sequencing and non-quantitative results. Recently we developed the enhanced CLIP-seq (eCLIP) methodology, which showed thousand-fold improved efficiency of generating high-throughput sequencing libraries from RBP profiling experiments and enabled highly robust and reproducible RBP target profiling through the incorporation of paired size-matched inputs. Here we will develop the eCLIP method for wide-spread use by the academic and commercial biotechnology industry in the following aims: 1. Develop an eCLIP kit, and perform optimization and stability testing to ensure robust data generation from a standardized kit format. 2. Perform alpha testing of a standardized eCLIP kit and protocol to validate experimental success and identify areas for further optimization. 3. Develop and validate standard conditions for various cell-types, tissues, and sample types (including flash-frozen versus fixed tissues, small sample amounts, and non-human samples). 4. Develop software tools for standard data processing and primary data analysis of eCLIP data, including integration with publicly available eCLIP data resources. Eclipse Bio is an ideal candidate to perform the aims described above due to our expertise in genomics and computational biology (particularly in the area of RNA processing), as well as in the starting of early-phase biology companies, make us ideal candidates to perform the research proposed above. The four aims above will take eCLIP from an academic research method to one that can be standardly performed by biomedical researchers in academia as well as commercial entities, without requiring extensive expertise in RNA biology. The development of standardized commercial kits to profile DNA binding protein targets by ChIP-seq rapidly led to large-scale adoption of this technique, and has provided significant benefits to studies of DNA binding proteins involved in various diseases; development of an eCLIP kit will similarly enable studies of RNA binding proteins. Additionally, our location in San Diego proximal to numerous academic research institutes (including UCSD and the Salk Institute) as well as biotechnology companies will provide scientific and commercialization expertise and assistance. [[currently 4 lines over 30 line limit]]
项目总结 转录后,RNA分子经历了一系列的处理步骤来调节剪接的 序列,RNA表达水平,亚细胞定位,以及翻译的起始和速度,并且每个 受RNA结合蛋白(RBPs)活性控制。RNA加工在正常情况下起着关键作用 发展和RNA加工的改变已被证明会导致家族性脊髓肌萎缩, 肌萎缩侧索硬化症和多种癌症类型。确定突变的RBP的RNA靶标 这些疾病是通向对这种疾病的机械性理解的关键的第一步,最终, 靶向疗法的发展。然而,识别RBP靶标的标准化方法 整个转录组都缺乏,因为他们需要大量的样本输入量,实验失败率很高 而且需要高扩增,导致大量的测序浪费和非定量结果。 最近我们开发了增强的Clip-Seq(ECLIP)方法,它显示了数千倍的 提高了从RBP图谱实验生成高通量测序文库的效率 通过结合成对的大小匹配的RBP靶标分析,实现了高度健壮和可重复性的靶标分析 投入。在这里,我们将开发eCLIP方法,供学术界和商界广泛使用 生物技术产业的以下目标: 1.开发eCLIP工具包,进行优化和稳定性测试,确保数据健壮 从标准化的套件格式生成。 2.执行标准化eCLIP试剂盒和协议的阿尔法测试,以验证实验成功 并找出需要进一步优化的领域。 3.开发和验证各种细胞类型、组织和样本类型的标准条件 (包括快速冷冻与固定组织、少量样本和非人类样本)。 4.开发用于eCLIP数据标准数据处理和初级数据分析的软件工具, 包括与公开可用的eCLIP数据资源的集成。 由于我们在基因组学方面的专业知识,eclipse Bio是实现上述目标的理想候选者 和计算生物学(特别是在RNA处理领域),以及在早期阶段的开始 生物公司,使我们成为执行上述研究的理想人选。以上四个目标 将把eCLIP从一种学术研究方法转变为一种可以由生物医学标准化执行的方法 学术界和商业实体的研究人员,而不需要在RNA生物学方面的广泛专业知识。 芯片序列快速分析DNA结合蛋白靶标商品化试剂盒的研制 导致这项技术的大规模采用,并为DNA结合的研究提供了显著的好处 参与各种疾病的蛋白质;eCLIP试剂盒的开发将类似地使RNA结合的研究成为可能 蛋白质。此外,我们在圣地亚哥的位置靠近许多学术研究机构(包括 UCSD和索尔克研究所)以及生物技术公司将提供科学和商业化 专业知识和援助。 [[当前超过30行限制的4行]]

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Alexander A Shishkin其他文献

Influence of RAR α gene on MDR1 expression and P-glycoprotein function in human leukemic cells
  • DOI:
    10.1186/1475-2867-5-15
  • 发表时间:
    2005-05-24
  • 期刊:
  • 影响因子:
    6.000
  • 作者:
    Tatjana P Stromskaya;Ekaterina Y Rybalkina;Tatjana N Zabotina;Alexander A Shishkin;Alla A Stavrovskaya
  • 通讯作者:
    Alla A Stavrovskaya

Alexander A Shishkin的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Alexander A Shishkin', 18)}}的其他基金

Unambiguous transcriptome-wide identification of microRNA:mRNA interactions through enhanced chimeric read amplification
通过增强嵌合读取扩增,在全转录组范围内明确识别 microRNA:mRNA 相互作用
  • 批准号:
    9909924
  • 财政年份:
    2019
  • 资助金额:
    $ 127.8万
  • 项目类别:
Development of chimeric read amplification into a robust method for profiling targets of specific microRNAs and global amplification of all microRNA:mRNA pairings transcriptome-wide
将嵌合读取扩增发展为一种强大的方法,用于分析特定 microRNA 的靶标以及所有 microRNA:mRNA 配对转录组范围的全局扩增
  • 批准号:
    10326159
  • 财政年份:
    2019
  • 资助金额:
    $ 127.8万
  • 项目类别:
A robust kit, standards, and software for identifying RNA binding protein targets
用于识别 RNA 结合蛋白靶标的强大试剂盒、标准品和软件
  • 批准号:
    9568006
  • 财政年份:
    2017
  • 资助金额:
    $ 127.8万
  • 项目类别:

相似海外基金

Investigating the Adoption, Actual Usage, and Outcomes of Enterprise Collaboration Systems in Remote Work Settings.
调查远程工作环境中企业协作系统的采用、实际使用和结果。
  • 批准号:
    24K16436
  • 财政年份:
    2024
  • 资助金额:
    $ 127.8万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
WELL-CALF: optimising accuracy for commercial adoption
WELL-CALF:优化商业采用的准确性
  • 批准号:
    10093543
  • 财政年份:
    2024
  • 资助金额:
    $ 127.8万
  • 项目类别:
    Collaborative R&D
Unraveling the Dynamics of International Accounting: Exploring the Impact of IFRS Adoption on Firms' Financial Reporting and Business Strategies
揭示国际会计的动态:探索采用 IFRS 对公司财务报告和业务战略的影响
  • 批准号:
    24K16488
  • 财政年份:
    2024
  • 资助金额:
    $ 127.8万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 127.8万
  • 项目类别:
    EU-Funded
Assessing the Coordination of Electric Vehicle Adoption on Urban Energy Transition: A Geospatial Machine Learning Framework
评估电动汽车采用对城市能源转型的协调:地理空间机器学习框架
  • 批准号:
    24K20973
  • 财政年份:
    2024
  • 资助金额:
    $ 127.8万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 127.8万
  • 项目类别:
    EU-Funded
De-Adoption Beta-Blockers in patients with stable ischemic heart disease without REduced LV ejection fraction, ongoing Ischemia, or Arrhythmias: a randomized Trial with blinded Endpoints (ABbreviate)
在没有左心室射血分数降低、持续性缺血或心律失常的稳定型缺血性心脏病患者中停用β受体阻滞剂:一项盲法终点随机试验(ABbreviate)
  • 批准号:
    481560
  • 财政年份:
    2023
  • 资助金额:
    $ 127.8万
  • 项目类别:
    Operating Grants
Our focus for this project is accelerating the development and adoption of resource efficient solutions like fashion rental through technological advancement, addressing longer in use and reuse
我们该项目的重点是通过技术进步加快时装租赁等资源高效解决方案的开发和采用,解决更长的使用和重复使用问题
  • 批准号:
    10075502
  • 财政年份:
    2023
  • 资助金额:
    $ 127.8万
  • 项目类别:
    Grant for R&D
Engage2innovate – Enhancing security solution design, adoption and impact through effective engagement and social innovation (E2i)
Engage2innovate — 通过有效参与和社会创新增强安全解决方案的设计、采用和影响 (E2i)
  • 批准号:
    10089082
  • 财政年份:
    2023
  • 资助金额:
    $ 127.8万
  • 项目类别:
    EU-Funded
Collaborative Research: SCIPE: CyberInfrastructure Professionals InnoVating and brOadening the adoption of advanced Technologies (CI PIVOT)
合作研究:SCIPE:网络基础设施专业人员创新和扩大先进技术的采用 (CI PIVOT)
  • 批准号:
    2321091
  • 财政年份:
    2023
  • 资助金额:
    $ 127.8万
  • 项目类别:
    Standard Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了